Eyes and Vision | VCH Research Institute

Recruiting

Evaluating the efficacy of a gene therapy to treat vision loss

The purpose of this study is to evaluate the efficacy and safety of a novel gene therapy in participants with wet age-related macular degeneration (nAMD), a significant cause of vision loss for people worldwide. Current standard of care therapies require life-long intraocular injections that are typically repeated every 4-12 weeks to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. As such, gene therapy RGX-314 is being developed as a potential one-time treatment for nAMD.

Status

Recruiting

Evaluating a drug treatment for severe thyroid eye disease

The purpose of this study is to evaluate the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily versus placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease.

Status

Recruiting

Using eye movements to understand cognitive and motor functions in Parkinson’s Disease

The purpose of this study is to test visual abilities and eye movements in patients with Parkinson's disease and healthy control participants and to link dysfunctions to cognitive abilities and disease severity.

Recruitment Poster

Status

Recruiting

Automated detection of autonomic dysreflexia via deep learning

The purpose of this study is to investigate if and how retinal blood vessels change after a spinal cord injury (SCI) and the associations of these changes with cardiovascular diseases. Using images of retinal blood vessels, we will develop a deep learning-based screening tool for autonomic dysreflexia, a cardiovascular complication unique to SCI.

Recruitment Poster

Status

Recruiting

First in Human (FIH) Study to Assess Safety and Efficacy of the CorNeat KPro for the Treatment of Corneal Blindness

The purpose of this study is to test the safety and efficacy of the CorNeat Keratoprosthesis, a synthetic cornea, for the treatment of corneal blindness.

Status

Recruiting

ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy

The purpose of this study is to assess the efficacy and safety/tolerability of three dose regiments of RVT-1401 in the treatment of active, moderate to severe Graves' Ophthalmopathy.

Status

Recruiting

Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease (CRISEPTED)

Thyroid eye disease is an autoimmune disorder affecting approximately 50% of individuals with autoimmune thyroid diseases resulting in enlargement of ocular muscles and may lead to congestion of the eyelids and ocular surface, ocular movement restriction and double vision, and optic nerve compression and loss of vision.

First line medical therapy is oral or intravenous corticosteroids (CS), which several studies have shown results in reduction of soft tissue congestion, but some studies suggesting that ocular restriction or visual loss may still occur in spite of CS therapy.

Status

Recruiting

A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

To compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack in subjects with NMO/NMOSD.

Status

Recruiting

Closed for Recruitment

Study of Ataluren in Patients With Aniridia (STAR)

This is a Phase 2, randomized, double-masked, placebo-controlled study of ataluren in patients with aniridia caused by a nonsense mutation. Patients will receive masked study drug for 48 weeks followed by open-label ataluren for another 48 weeks. Safety and efficacy will be assessed.

Status

Closed for Recruitment

Efficacy and Safety of RTH258 Versus Aflibercept

The purpose of this study is to compare RTH258 ophthalmic solution for intravitreal (IVT) injection at two dosage levels to aflibercept solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.

Status

Closed for Recruitment

Efficacy and Safety of RTH258 Versus Aflibercept

Status

Closed for Recruitment

Treatment for CI-DME in Eyes With Very Good VA Study (Protocol V)

Although multiple studies have clearly demonstrated that ranibizumab therapy is more effective than laser alone for vision gain and avoiding vision loss in patients with central-involved Diabetic Macular Edema (DME), only eyes with poor visual acuity, such as a visual acuity letter score of 78 or worse (approximate Snellen equivalent of 20/32 or worse) were eligible. Eyes that have central-involved DME with "good" visual acuity (20/25 or better) have not been addressed systematically by recent studies for treatment of DME.

Status

Closed for Recruitment

A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis (VISUAL III)

There is an unmet medical need in non-infectious intermediate-, posterior- and pan uveitis. These types of uveitis are at a higher risk for vision loss compared to anterior uveitis. Patients with these types of uveitis are often treated with chronic corticosteroids. The use of chronic corticosteroids is linked with predictable long-term side effects. The objective of this study is to evaluate the long term efficacy and safety of adalimumab subjects with non-infectious intermediate-, posterior- or pan-uveitis.

Status

Closed for Recruitment

A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis (VISUAL III)

The objective of this study is to evaluate the long term efficacy and safety of adalimumab subjects with non-infectious intermediate-, posterior- or pan-uveitis.

Status

Closed for Recruitment

Subscribe to Eyes and Vision